Background Ulcerative colitis (UC) is a chronic inflammatory disorder. Clinically, there are periods of pain in abdomen and bloody diarrhea. The used medication induce clinical diminution, but with many difficulties.
Aim of the study Evaluation the beneficial outcomes of rebamipide and microvesicles come from mesenchymal stem cells on treatment of induced colitis.
Material and methods Fifty adult male albino rats were divided into 5 groups. Group I was the control group. Group II rats received intra-colonic instillation of 1 ml/rat/day of 5% acetic acid (5% v/v) for 3 sequential days. Group III Rats were received a suspension of (1 % rebamipide and 1.5% carboxy-methyl cellulose), intra-colonic in a dose 1 mL/kg/day after provocation of colitis for 14 days . Group IV rats were given out a single dose of 15 μg of microvesicles dissolved in 0.5 ml of phosphate buffered solution (PBS) delivered intravenous in caudal vein after provocation of colitis. Group V rats were given microvesicles and Rebamipide as Group ПI and Group IV after provocation of colitis. The colon sections were managed and examined using histological and immunohistochemical study.
Results Group II showed patchy ulceration with loss of surface epithlium and under-lying connective tissue. There is infiltration of mononuclear cells and congested blood vessels in lamina propria and sub mucosa. Group III showed near-normal mucosa with surface columnar cell and goblet cells in some areas with discontinuity in certain areas. Group IV showed almost intact mucosa. Group V showed intact mucosa with surface absorptive cells and goblet cells close to control group.
Conclusion: Each of rebamipide and microvesicle improved the prompted ulcerative colitis, but their combination was more effective